Zhejiang Haichang Bio-Tech Co., Ltd.

Primary study objective: To investigate the pharmacokinetic characteristics of a single subcutaneous infiltration injection of the test preparation bupivacaine liposome injection [Specification: 20 ml: 266 mg (13.3 mg/ml)], produced by Zhejiang Anlikang Pharmaceutical Co., Ltd. and the reference preparation bupivacaine liposome injection (Exparel® Specification: 266 mg/20ml (13.3 mg/ml): Pacira Pharmaceuticals, Inc.) in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two preparations after a single dose in the fasting state. Secondary study objective: To investigate the safety of the test preparation bupivacaine liposome injection (Specification: 20 ml:266 mg (13 .3 mg/ml)) and the reference preparation bupivacaine liposome injection (Expare®) (Specification: 266 mg/20 ml (13.3 mg/ml)) in healthy participants.

The primary study objective is to study the pharmacokinetics of a single dose of the test preparation irinotecan liposome injection (specification: 43 mg/10 mL, produced by Dongying Tiandong Pharmaceutical Co., Ltd. on behalf of Zhejiang Haichang Biopharmaceutical Technology Co., Ltd.) and the reference preparation irinotecan liposome injection (trade name: ONIVYDE®, specification: 43 mg/10 mL; certified by Les Laboratoires Servier, produced by Les Laboratoires Servier Industrie) in patients with advanced pancreatic cancer, and to evaluate the bioequivalence of the two preparations. The secondary study objective is to study the safety of the test preparation irinotecan liposome injection 43 mg/10 mL and the reference preparation irinotecan liposome injection (trade name: ONIVYDE®) 43 mg/10 mL in patients with advanced pancreatic cancer.